NOW APPROVED: EMROSI™ (Minocycline Hydrochloride) Extended-Release Capsules, 40mg

Learn More

NOW APPROVED

Journey Medical Corporation Announces the U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride) Extended-Release Capsules, 40mg for Treatment of Papulopustular Rosacea.

Learn More

Latest Financial Results

Mar 26, 2025 • 4:01 PM EDT

FY 2024 Year End Results

Fiscal Year Ended Dec 31, 2024

Earnings Release
PDF HTML
Audio
Earnings Webcast
10-K Filing
PDF HTML
XBRL
ZIP XLS HTML

Latest News

View all news

Latest Financial Results

View All SEC Filings

FY 2024

Fiscal Year Ended Dec 31, 2024

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2024

Report Links

Contacts

Corporate

Journey Medical Corporation
9237 East Via De Ventura
Suite 105
Scottsdale, AZ 85258
T: 480-434-6670
contact@jmcderm.com

Investor Relations

Jaclyn Jaffe
T: 781-652-4500
ir@jmcderm.com

Transfer Agent

VStock Transfer
Allison Niccolls
allison@vstocktransfer.com